Hilleman CEO on why new cholera vaccine could be 'high impact'

Hilleman Laboratories, the joint venture between Merck & Co and Wellcome Trust, and Gotovax AB, a University of Gothenburg spin-off biopharma firm, have outlined plans to develop a cut-price oral cholera vaccine that could potentially address some of the key limitations of existing products for the deadly disease.